Результаты поиска

Nanotherapeutics in the EU: an overview on current state and future directions.

The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug's therapeutic index, and reduce a drug's immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most suc

Совпадение в полном тексте источника
… centralized procedure; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; EL, Greece; EMA, European Medicines Agency; ES, Spain; FI, Finland; FR, France; HMA, Heads of Medicines Agencies; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; LT, Lithuania; LU, Luxembourg; LV, Latvia … fragment antigen binding; Fl, Finland; FR, France; Glu, glutamic acid; HIV, human immunodeficiency virus; HGH, human growth hormone; HMA, Heads of Medicines Agencies; HR, Croatia; HU, Hungary; IE, Ireland; im, intramuscular; IS, Iceland; IT, Italy; iv, intravenous; LT, Lithuania; LU, Luxembourg; LV, Latvia …

Ассоциация базового липополисачарида и протеина с расширенным уровнем инвалидности, динамика развития у пациентов с повторным множественным склерозом: экспериментальное исследование.

Прогнозирование развития этой болезни на ранней стадии возбудителя наиболее часто встречающегося вида множественного склероза (MS), известного как релапсирующий множественный склероз (RRMS), имеет важное значение для быстрого изменения методов лечения, нацеленного на сокращение рецидивов и инвалидности в клинических условиях. В этом исследовании приняли участие в общей сложности 58 пациентов с системой RRMS, число которых в рамках расширенной шкалы взносов для инвалидов (EDSS) составляет менее 4. Проведена базовая магнитно-резонансная съемка (MRI) и проведена оценка повреждений мозга и спинног

Совпадение в полном тексте источника
… Procedure and Participants The pilot study was conducted from February 2022 to September 2024 in the tertiary hospital in Riga, Latvia. …

Лечение болезней с использованием медицинских средств 8-Item Шкала соответствия лекарствам с повышенным рискомMMAS-8Систематический обзор с обобщением информации.

Соблюдение лекарств является одним из ключевых факторов, определяющих клинические результаты лечения пациентов с неинфекционными хроническими заболеваниями, для которых часто требуется долгосрочная фармакотерапия, непрерывное наблюдение и привлечение пациентов. В ходе этого систематического обзора была проведена оценка использования 8-item Шкала соответствия лекарствам с повышенным рискомMMAS-8) для оценки соответствия взрослых лекарственным препаратам неинфекционным хроническим заболеваниям и резюме уровней присоединения, сопутствующих факторов и методологических характеристик, сообщаемых в р

Совпадение в полном тексте источника
… adherence Khedr et al. [ 24 ] Egypt Multiple sclerosis Cross-sectional 97 Hospital Self-administered Standard No Satisfaction predicts adherence Khaiser et al. [ 25 ] India Chronic diseases Cross-sectional 310 Hospital Self-administered Standard No Relationship with quality of life Gavrilova et al. [ 26 ] Latvia …

Анализ тенденций и межнациональный анализ неравноправия в отношении иммунизированных подстрекательских заболеваний у детей и подростков в возрасте от 10 до 24 лет в период с 1990 по 2021 год.

IMID - это хронические подстрекательские заболевания, вызываемые дисрегулированием иммунной системы и затрагивающие многочисленные системы и органы. Дети и подростки в возрасте от 10 до 24 лет относятся к группам повышенного риска, и глобальное бремя является значительным. МЕТОДЫ: Используя самые последние данные о глобальном бремени заболеваний (ГБЗ) 2021 года, мы использовали регрессионный анализ " Компонт " , корреляционный анализ социально-демографического индекса (ИОД) и межнациональный анализ справедливости для разъяснения диспропорциональных различий в бремени ИМНИ среди детей

Совпадение в полном тексте источника
… The lowest AD incidence rates were in Rwanda (72.35, 95% CI: 60.18 to 84.81), Romania (71.13, 95% CI: 58.90 to 84.25), and Latvia (49.01, 95% CI: 42.37 to 56.12). …

P941 – P1197

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Опыт, накопленный пациентами в ходе видеоконференций: качественный систематический обзор.

Консультация Video (VC) приобрела жизненно важное значение для улучшения доступа к медицинскому обслуживанию во время пандемии COVID-19 и остается таковой. Несмотря на доказательства эффективности, проблемы, включая технологическую грамотность и несоответствия в опыте, указывают на необходимость проведения более широких исследований, ориентированных на пациентов. Несмотря на то, что пациенты ценят удобство ВК, проблемы, возникающие во время сложных проблем и предпочтения пациентов в плане личного ухода, сохраняются. Обобщение качественных исследований дает представление о фрагментированном пон

Совпадение в полном тексте источника
… Grinfelde, 2022 | Face-to-Face with the Doctor Online: Phenomenological Analysis of Patient Experience of Teleconsultation | Human Studies | Latvia | Mixed; patients with VC experience | 14 | Phenomenological interview | Phenomenologically grounded qualitative research | “This study aims to determine … Demographics of included studies The 13 included studies were conducted in six countries (Canada, the USA, Norway, Denmark, Latvia and Australia), with publication dates from 2015 to 2023. …

Access to novel cancer medicines in Europe: inequities across countries and their drivers.

BackgroundAn increasing number of cancer medicines are being developed and approved. Access to these medicines is important for improving patient outcomes and overall quality of care, yet achieving equitable access across countries in Europe is challenging.MethodThis study reviews inequities in access to novel cancer medicines in countries of the European Union (EU) and European Economic Area (EEA), and neighboring countries, at three critical stages: regulatory approval, reimbursement approval, and use in clinical practice. It also examines reasons contributing to these inequities. The analys

Совпадение в полном тексте источника
… Spending on cancer medicines (measured in list prices and therefore overestimated) ranged from €31 per capita in Latvia to €195 per capita in Austria, with countries in Western Europe tending to record the highest spending levels, followed by countries in Southern and Northern Europe, and CEE countries …

Global welfare burden of hematologic malignancies from 2015 to 2023.

Hematologic malignancies cause premature mortality and disability across the life course, but their welfare burden is difficult to compare across countries. We monetized global burden of disease (GBD) 2023 disability-adjusted life years (DALYs) for major hematologic malignancies in 188 countries from 2015 to 2023 using a value of lost welfare framework incorporating purchasing power parity adjusted gross domestic product (GDP), income transfer, age-specific valuation, and discounting. Global leukemia-related value of lost welfare (VLW) increased from US$1.40 trillion to US$1.70 trillion, while

Совпадение в полном тексте источника
… For multiple myeloma, the leading ratios were observed in Bolivia (4.30%), Belarus (2.41%), Trinidad and Tobago (1.93%), Latvia (1.83%), and Lithuania (1.67%). Hodgkin lymphoma-related VLW/GDP was highest in Bolivia (1.50%), Georgia (0.79%), Belarus (0.59%), Ukraine (0.54%), and Moldova (0.53%). …

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials eva

Совпадение в полном тексте источника
… After additional directed evolution and selection oncolytic ECHO-7 virus was later registered in Latvia in 2004 as Rigvir [ 94 ]. Several case reports demonstrate good tolerability and moderate efficacy of Rigvir in combination with surgery for the treatment of advanced melanoma [ 111 , 112 ]. … Virusnyi Onkoliz i Iskusstvennaya Geterogenizatsiya Opukholei (Viral Oncolysis and Artificial Heterogenization of Tumors) Riga, Latvia: 1969. Experience in treating patients with gastrointestinal tumors by live enterovirus vaccines; pp. 23–26. 106. …

Oncolytic Viruses for Cancer Therapy in Dogs.

Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. This systematic review summarizes current knowledge on the application of oncolytic viruses (OVs) in canine cancer treatment, focusing on their mechanisms of action, safety profiles, and clinical efficacy. We evaluate diverse OV platforms, includin

Совпадение в полном тексте источника
… The safety and efficacy of several OVs have been established in human clinical trials, and certain oncolytic viral therapeutics have received regulatory approval in the United States, Latvia, China, and Japan [ 6 , 7 , 8 , 9 ]. …

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Objective To determine the availability of data on overall survival and quality of life benefits of cancer drugs approved in Europe.Design Retrospective cohort study.Setting Publicly accessible regulatory and scientific reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013.Main outcome measures Pivotal and postmarketing trials of cancer drugs according to their design features (randomisation, crossover, blinding), comparators, and endpoints. Availability and magnitude of benefit on overall survival or quality of life determined at time of approval and after marke

Совпадение в полном тексте источника
… EP is a member of Health Projects for Latvia, which is affiliated to Health Action International, and a board member of the Health Action International Europe Association. …

Review of cancer therapies for the perioperative physician.

Advances in cancer treatments over the past decades combining chemotherapy with novel technologies in immunotherapies, radiation therapies, and interventional radiology have prolonged life expectancy. Patients have more options for treatments of their primary or metastatic diseases. Increased procedural techniques amid an aging population with multiple comorbidities present risks and challenges in the perioperative period.Chemotherapy remains the mainstay of cancer treatment, can be given intraoperatively, and is combined with other treatment modalities. Immunotherapy is particular to cancer c

Совпадение в полном тексте источника
… These include Rigvir (Riga virus since 2004) for the treatment of melanoma in Latvia (Alberts et al. 2016 ), Oncorine (H101since 2005) for use in combination therapy for the treatment of head and neck cancers in China (Liang 2018 ), and talomogene (T‐VEC or Imlygic) (Liu et al. 2003 ), a genetically …

Estimation of Future Patient Populations Eligible for Radioligand Therapies in the EU and the UK: A Modelling Study.

BackgroundThe eligible patient population for radioligand therapies (RLTs) has the potential to grow rapidly in the coming years. European healthcare systems may be ill-prepared to provide the additional treatment capacity required on top of current workload. To address this challenge, data on the size of the eligible patient pool and the potential utilisation of RLTs are needed.MethodsThe maximum pool of patients theoretically eligible for RLTs over the next decade was estimated for the 27 EU member states (EU-27) using incidence data, and additionally for France, Germany, Italy, Spain (EU-4)

Совпадение в полном тексте источника
… 10,459,782 | 570 | 200–300 | 1300–2100 | 2600–3800 Hungary | No | 9,689,010 | 560 | 200–300 | 1100–1900 | 2400–3400 Ireland | No | 5,060,004 | 590 | 100–200 | 700–1300 | 1700–2500 Italy | Yes | 59,030,133 | 400 | 1400–1700 | 7300–12,200 | 15,300–22,200 Italy (∗) | Yes | | | 4800 | 21,500 | 25,500 Latvia …

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.

Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish th

Совпадение в полном тексте источника
… It acts as an immunomodulator with anti-tumor effect, and it is approved for the treatment of melanoma, the local treatment of skin and subcutaneous metastases of melanoma, and for the prevention of relapse and metastasis after radical surgery in Latvia, Georgia, Armenia, and Uzbekistan [ 67 ]. …

A multicountry ecological study of cancer incidence rates in 2008 with respect to various risk-modifying factors.

Observational and ecological studies are generally used to determine the presence of effect of cancer risk-modifying factors. Researchers generally agree that environmental factors such as smoking, alcohol consumption, poor diet, lack of physical activity, and low serum 25-hdyroxyvitamin D levels are important cancer risk factors. This ecological study used age-adjusted incidence rates for 21 cancers for 157 countries (87 with high-quality data) in 2008 with respect to dietary supply and other factors, including per capita gross domestic product, life expectancy, lung cancer incidence rate (an

Совпадение в полном тексте источника
… Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Fiji, Finland, France, Georgia, Germany, Greece, Guatemala, Guyana, Hungary, Iceland, Iran, Ireland, Israel, Italy, Jamaica, Japan, Kazakhstan, Korea (Republic), Kuwait, Kyrgyzstan, Latvia …

Обязательный экзамен по патологии: лишний или необходимый?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Safety and efficacy of antigen-specific therapeutic approaches for multiple sclerosis: Systematic review.

INTRODUCTION: The objective of this systematic review is to evaluate the efficacy and safety of antigen-specific tolerance-inducing therapeutic approaches (products based on peptides, DNA and T cells) versus placebo or other comparators, where possible, in adult multiple sclerosis (MS) patients. METHODS: PubMed, CINAHL, Web of Science, Cochrane and International Clinical Trials Registry Platform, ClinicalTrials.gov were searched for published and unpublished studies. Screening, critical appraisal, and data extraction for included studies were carried out by two independent reviewers. For effi

Совпадение в полном тексте источника
… Chataway, et al. 2018. b Russia, Latvia Phase IIa, multicenter, single-arm, proof-of-concept trial Subjects with RMS aged 18–55 years, having ≥1 documented relapse in the previous 12 months or 2 relapses within the previous 24 months), EDSS ≤5.5, positive HLA-DRB1*15 Intervention: ATX-MS-1467 (cocktail …

15th Конгресс Европейской ассоциации клинической фармакологии и терапии (ЕАКПТ)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Гибридные нанопчасти на основе гиалюронной кислоты в качестве перспективных перевозчиков Интранасальной администрации диметилФумарата.

ПППОСА: Диметилфумарат (ДМФ) - пероральная терапия с релапсирующим множественным склерозом, быстро метаболизируется в монометилфумарат. Оральное управление DMF вызывает желудочно-кишечный дискомфорт, вызывая вынос лечения. Цель настоящего исследования заключается в разработке новаторской формулировки для управления носовым слоем ДМФ. Гибридные наночастицы (LPN) липидового полимера были разработаны для повышения устойчивости DMF, ограничения побочных эффектов желудочно-кишечного кишечника и увеличения биодоступности головного мозга за счет нацеливания нос на мозг.МЕТОДЫ: С помощью методов магни

Совпадение в полном тексте источника
… After filling both the acceptor and donor compartments, the plates were incubated in an orbital shaker–incubator (ES-20, Biosan, Riga, Latvia, LV) at 25°C and 200 rpm for 5 h, respectively. In the experimental setup, samples were assessed both in the presence and absence of mucin 5% (w/v). …

Abstracts of the 19th International Congress on Neuromuscular Diseases 7th – 11th July 2026

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.